Perturbation-Based Modeling Unveils the Autophagic Modulation of Chemosensitivity and Immunogenicity in Breast Cancer

Isaac Quiros-Fernandez1,2,3, Lucía Figueroa-Protti1,2, Jorge L Arias-Arias1,4

  • 1Research Center for Tropical Diseases (CIET), Laboratory of Tumor Chemosensitivity (LQT), Faculty of Microbiology, University of Costa Rica, San José 11501-2060, Costa Rica.

Metabolites
|September 26, 2021
PubMed

Insights

Metabolic regulation of autophagy can enhance chemotherapy effectiveness in metastatic breast cancer by triggering immunogenic cell death (ICD). This approach aims to overcome drug resistance and improve patient survival rates.

Area of Science:

  • Oncology
  • Cell Biology
  • Metabolic Pathways

Background:

  • Chemotherapy is standard for metastatic breast cancer but has limited efficacy and significant side effects.
  • Novel therapeutic targets are crucial to improve patient survival rates.

Purpose of the Study:

  • To investigate the link between autophagy regulation, damage-associated molecular patterns (DAMPs), and immunogenic cell death (ICD) in breast cancer.
  • To explore strategies for modulating autophagy to enhance chemotherapy response.

Main Methods:

  • Validated an mCHR-GFP tandem LC3 sensor to monitor autophagic flux.
  • Assessed basal autophagy and responses to regulators across different breast cancer cell lines.
  • Examined interactions between autophagy modulators and chemotherapeutics for cytotoxicity and ICD induction.

Main Results:

  • Autophagy levels and responses vary significantly among breast cancer cell lines.
  • Developed a model to understand chemotherapy's impact on autophagic flux and guide modulation strategies.
  • Identified specific interactions between autophagy modulators and chemotherapeutics.

Conclusions:

  • Metabolic regulation of autophagy shows promise in overcoming chemotherapy resistance.
  • Targeting autophagy can enhance chemotherapy efficacy by inducing immunogenic cell death (ICD).
  • This strategy offers a potential new avenue for treating metastatic breast cancer.